Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)

37 articles about Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)

• XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences

  7/15/2021

  XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.

• 

  Clinical Catch-Up: September 2-8

  9/9/2019

  Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.

• Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand

  7/9/2019

  Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Kuros Biosciences Appoints Chief Medical Officer

  3/8/2016

• Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which Is Renamed Kuros Biosciences

  1/20/2016

• LSP’s Portfolio Company Kuros Biosciences Closes Merger With Cytos And Is Now Listed As Kuros Biosciences Ltd On Swiss Stock Exchange

  1/19/2016

• Cytos Biotechnology Ltd. Will Be Renamed Kuros Biosciences , Constitutes Its Board Of Directors And Appoints Executive Officers

  1/8/2016

• VC-Backed Kuros Biosurgery Merges with Cytos Biotech

  12/3/2015

• Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study

  4/14/2014

• Cytos Biotechnology AG Rights Offering Oversubscribed - CHF 24.3 Million Raised

  11/18/2013

• Cytos Biotechnology AG to Host Investor and Analyst R&D Day in New York City

  10/17/2013

• Cytos Biotechnology AG Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma

  9/9/2013

• Cytos Biotechnology AG Reports Second Quarter 2013 Financial Results and Recent Developments

  8/6/2013

• A*STAR and Cytos Biotechnology AG Bring Singapore's First Influenza Vaccine to Clinical Testing

  5/17/2013

• Cytos Biotechnology AG Reports First Quarter 2013 Financial Results and Recent Development

  4/25/2013

• The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology AG’s CYT003 for the Treatment of Allergic Asthma

  3/13/2013

• Cytos Biotechnology AG VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine

  2/4/2013

• Cytos Biotechnology AG Reports Third Quarter 2012 Financial Results, Recent Development and Outlook

  11/6/2012

• Cytos Biotechnology AG Appoints Dr. Christian Itin as Chief Executive Officer

  10/9/2012